title: Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.
abstract: Fifty patients with advanced-stage Hodgkin's disease (HD) who relapsed or failed to respond to multiple regimens of combination chemotherapy were entered onto two autologous bone marrow transplantation (AuBMT) protocols. Twenty-eight patients who did not have prior radiation therapy were treated with protocol A. Protocol A consisted of reinduction with conventional doses of combination chemotherapy followed by boost local-field irradiation to areas of residual disease and hyperfractionated accelerated total lymphoid irradiation (TLI). Chemotherapy consisted of high-dose etoposide (VP-16) and cyclophosphamide followed by infusion of cryopreserved, unpurged autologous bone marrow. Twenty-two patients who have had prior radiation therapy were treated with protocol B. Protocol B consisted of reinduction with conventional doses of chemotherapy followed by involved field radiation therapy (when tolerance to residual disease has not been previously reached). High-dose chemotherapy regimen consisted of cyclophosphamide, carmustine (BCNU), and VP-16 (CBV) followed by autologous bone marrow transplantation. Of the 28 patients in protocol A, 5 patients died during the immediate peritransplant period, 5 patients progressed within six months, and 2 of them died. Two patients relapsed 13 and 39 months post transplant; 1 of them was reinduced into a complete remission (CR). Seventeen patients (61%) are disease free (16 patients in continuous complete remission), 12-54+ months (median 25+ months) following completion of therapy. Of the 22 patients in protocol B, 1 died of cytomegalovirus pneumonitis, and 11 relapsed. Ten patients (45%) are alive and disease free 16-42+ months (median 23+ months) after therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York.
authors.forename: J
authors.initials: J
authors.lastname: Yahalom
authors.forename: S
authors.initials: S
authors.lastname: Gulati
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D002423:Cause of Death; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D015182:Lymphatic Irradiation; D012008:Recurrence; D015996:Survival Rate
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D002330:Carmustine